Akebia Therapeutics Inc

akebia.com

Akebia Therapeutics Inc (NASDAQ: AKBA) is a biopharmaceutical company focused on the development and commercialization of therapeutics for kidney disease. The filing excerpts provided do not contain sufficient detail to describe the revenue model, product portfolio, competitive position, geographic footprint, or financial metrics with the specificity required. Based solely on the available filing content, no further factual claims about Akebia's business operations, revenue streams, customer base, or market position can be supported.

Peers: AquaBounty Technologies Inc Atreca, Inc. BioVie Inc Unity Biotechnology, Inc. Disc Medicine Inc GT Biopharma Inc EOM Pharmaceutical Holdings, Inc. Palatin Technologies Inc Solid Biosciences Inc

Source: SEC 10-K, filed 2026-02-26

Dive deeper

Financial Snapshot

Revenue

TTM

$219.1M

Gross Margin

TTM

80.48%

Net Income

TTM

-$29.67M

Current Assets

2026 Q2

$229.6M

Current Liabilities

2026 Q2

$160.9M

Current Ratio

2026 Q2

142.7%

Total Assets

2026 Q2

$349.7M

Total Liabilities

2026 Q2

$324.6M

Book Value

2026 Q2

$25.02M

Cash

2026 Q2

$155.5M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

$29.46M

Stock Price

Market Cap: $265.58 Million